Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT one-stage cell therapy for focal knee cartilage lesions
NL-OMON37740Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2013
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous chondrons + allogeneic mesenchymal stromal cells in chondral knee defect, sponsored by University Medical Center Utrecht. Primary endpoints: Clinical safety and Feasibility. Started Apr 2013; status: active, not recruiting.
02
Drugs
autologous chondrons + allogeneic mesenchymal stromal cells
03
Conditions
chondral knee defect
Beyond the preview
Go deeper on NL-OMON37740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37740.